Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoLeap-HCC: Pembrolizumab and Lenvatinib in Resectable HCC
NCT05389527Phase 2Active, not recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Sep 2022
- Primary completion
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and lenvatinib in hepatocellular carcinoma (HCC), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Major Pathological Response at 24 weeks. Started Sep 2022; status: active, not recruiting.
02
Drugs
pembrolizumablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05389527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05389527.